BACKGROUND Early reperfusion in the setting of an ST-elevation myocardial infarction is utmost importance. However, to provide optimal care to patients with ST-segment elevated myocardial infarction (STEMI) is challenging. If a patient suffers from chest pain and calls the emergency number, initiation of a cascade of actions leads to a diagnosis, start of treatment and reperfusion of the infarcted myocardium. Previous studies have shown that reporting or transmitting prehospital ECG to the emergency department is an important part of treatment for patients with STEMI. The main benefit of prehospital ECG is its potential to reduce the overall treatment time to administration of reperfusion therapy. Furthermore, prehospital ECG enhances early arrival and triage to the emergency department, which is associated with increased use of reperfusion interventions and shortened time to treatment. However, it remained a challenging issue to set up prehospital ECG in Taiwan because of involvement of complicated multidisciplinary team work. Therefore, we reported first successful experience of establishment of pre-hospital ECG in Kaohsiung city.
METHODS A multidisciplinary team among Kaohsiung Veterans General hospital, fire bureau and department of health, Kaohsiung city government was organized since Sep, 2011. The key interventions include to establish prehospital automatic interpretation ECG system with immediate ECG transmission over mobile networks, to design a ECG exam accessory device, to set up a incentive and auditing system, to arrange EMT educational program, to set up a standard operative procedure with transfer to appropriate hospital and Asian first ambulance prehospital mobile transmit ECG system. The consecutive chest pain patients received ambulance ECG exam were enrolled from Jan. 2011 to Feb. 2013 in 6 different fire brigades at Kaohsiung city. The patients were divided into three groups: pre-interventional group from Jan to Dec 2011, Interventional group from Jan 2012 to Feb 2013 and post-interventional group from March 2013 to Feb 2014. The ECG implementation rate is defined as chest pain patients received ambulance ECG exam divided by all patients with chest pain.
RESULTS
We developed an ECG exam accessory device, which could shorten ECG exam from 252 seconds to 30 seconds. The number of monthly chest pain patients received ambulance ECG exam increased from zero patient in pre-interventional group, to 0.4 patients in interventional group and to 14.2 patients in post-interventional group (p<0.001).The ECG implementation rate increased from 0% in preinterventional group, to 0.6% in interventional group to 33.6% in post-interventional group (p<0.001). Total 14 patients with STEMI was detected in 175 chest pain patients received ambulance ECG exam. In these STEMI patients, average door to balloon time was 53.5 minutes, average ischemia to balloon time was 111 minutes and inhospital mortality was 0%.
CONCLUSION The key factor to establish pre-hospital ECG system in Kaohsiung city is cooperation of hospital, fire bureau and department of health of government. Furthermore, comprehensive EMT education program and development of an ECG exam accessory device were also critical to set up the pre-hospital ECG system. RESULTS Of the 144 patients studied, Average age was 68.3 years old and 82.3% was male. Lesion characteristics contained 63 ST-elevated myocardial infarction (STEMI) (44%), 14 non-STEMI (9%), 19 unstable Angina pectoris (uAP) (13%) and 48 stable angina pectoris (SAP) (34%). Procedural success (device pass the lesion) was 97.8%. Treatable coronary perforation occurred in 3 cases (2 cases were patients with STEMI). 30 days mortality of STEMI patients was 5%.
CONCLUSION ELCA is feasible and safe device for the treatment of patients with both patients with SAP and acute coronary syndrome. Further investigations will be required with larger number of patients to establish the effectiveness of ELCA. BACKGROUND Statin (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), given before percutaneous coronary intervention (PCI) was proven to reduce Major Cardiovascular Events (MACE) in patient with stable angina as well as acute coronary syndromes through it\'s pleiotropic effect. Nevertheless, the debate regarding statin administration before primary PCI (PPCI) in STEMI patients is still on the rise. The aim of this study is to establish therapeutic effect of high dose atorvastatin (80 mg) and placebo before primary PCI on microvascular perfusion in STEMI patient using index of microcirculatory resistance (IMR). IMR are specific and quantitative assessment of coronary microvascular dysfunction, reliable on-site predictors of short-term myocardial viability and left ventricle functional recovery of patients undergoing primary PCI for STEMI.
METHODS This study is a double blind randomized controlled trial. A high loading dose of atorvastatin (80 mg) or placebo was administered before PPCI. Samples were taken from the population of STEMI patients which underwent PPCI and meet inclusion and exclusion criteria. The primary end point of this study is IMR. After successful primary percutaneous coronary intervention, IMR was measured using a pressure-temperature sensor-tipped coronary guidewire. 13 Chonbuk National University Hospital, Korea (Republic of) BACKGROUND It has been well known that new P2Y12 receptor inhibitors (RI; prasugrel or ticagrelor) could improve clinical outcomes in patients with acute myocardial infarction (AMI). However, there were little data about the impact of new P2Y12 RI in Korean patients with AMI. Therefore, we compared the short-term clinical outcomes between new P2Y12 RI and clopidogrel in patients with AMI undergoing successful percutaneous coronary intervention (PCI).
METHODS Between November 2011 and August 2014, a total of 4,029 patients (3,186 patients were prescribed clopidogrel and 843 patients new P2Y12 RI [474 patients prasugrel and 369 patients ticagrelor]) with AMI undergoing successful PCI were included from Korea Acute Myocardial Infarction Registry-National Institute of Health. The patients older than 75 years, weight< 60 kg, or with a history of stroke and with in-hospital switching among 3 antiplatelet agents were excluded. The propensity score matching (802 pairs) were performed in order to compare the in-hospital clinical outcomes between new P2Y12 RI and clopidogrel after adjusting for baseline clinical and procedural confounders. METHODS A Database search 0f Chungbuk Regional cardiovascular center was conducted (January 2010-August 2014). Platelet function test and genetic studies were included where clopidogrel was initiated in conventional PCI in the ischemic heart disease. RESULTS A total of 567 patients with coronary artery disease treated by PCI were enrolled. The level of P2Y12 reaction unit (PRU) of the patients with CYP*2 or*3 heterozygote or CYP*2/*2 or *2/*3 or *3/*3 was significantly higher than with CYP*1/*1 or *1/*17(209AE86.8 (extensive metabolizers, EMs) vs. 228AE87.1 (intermediate metabolizers, IMs) vs. 243AE84.4 (poor metabolizers, PMs), p ¼0.006, 1 way ANOBA). The frequency of high on-treatment clopidogrel platelet reactivity (HPR) was also significantly higher in IMs and PMs (p ¼ 0.002). At1-year follow-up, the major cardiac adverse event occurred more frequently inpatients with high on-treatment clopidogrel platelet reactivity compared with patients without high on-treatment clopidogrel platelet reactivity, when platelet function was evaluated with the Verify Now P2Y12 assay (23 (9.3%) vs. 27 (7.5%), p¼0.27) without statistical significance. Kaplan-Meier test for MACE-free survival did not showed significant difference in survival analysis between High on-treatment clopidogrel platelet reactivity and nonHigh on-treatment clopidogrel platelet reactivity group. At 1-year
